Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (5): 862-865.doi: 10.3969/j.issn.1673-8225.2010.05.024

Previous Articles     Next Articles

Reparation of skin donor site wound using recombinant human epidermal growth factor

Guo Xing1, Tan Mei-yun2, Guo Li1, Xiong Ai-bing1, Li Yue-gang 1, He Xiao-chuan1   

  1. 1 Department of Burns and Plastic Surgery, 2 Department of Orthopaedics, Affiliated Hospital of Luzhou Medical College, Luzhou  646000, Sichuan Province, China
  • Online:2010-01-29 Published:2010-01-29
  • Contact: Tan Mei-yun, Doctor, Attending physician, Department of Orthopaedics, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China
  • About author:Guo Xing★, Master, Attending physician, Department of Burns and Plastic Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China gx412@126.com

Abstract:

BACKGROUND: The traditional treatment for skin donor site wound was focus on anti-infection and wound protection, which took a long time for healing. Studies demonstrated that recombinant human epidermal growth factor (rhEGF) has accelerated effect on epidermal regeneration.
OBJECTIVE: To observe the effect of rhEGF on wound healing of skin donor site.
METHODS: A total of 32 cases needs wound healing by skin grafting were collected, including 18 males and 14 females. The 32 skin graft donor site wounds were randomly divided into control and treatment groups. In the treatment group, the absorbent gauze was sprinkle soaked with rhEGF (15 mL/ramus, 2 000 IU/mL) and covered the donor site, twice per day. In the control group, donor site was covered by physiological saline gauze and wrapped with dressing, twice per day. After 48 hours, semi-exposed therapy was performed. The healing time of wounds, the systemic and local adverse reactions of patients and blood routine examination and renal function detection prior to and after treatment were observed.
RESULTS AND CONCLUSION: The healing time of wound in the rhEGF treatment group was shorter than that in the control group with significant differences (P < 0.01). No Adverse events or side effects were observed in the rhEGF treatment group. rhEGF can shorten wound healing time, reduce scar hyperplasia, and accelerate epithelization at the graft donor.

CLC Number: